PARP1 and breast carcinoma: Further, CHD4 depletion could increase sensitivity to trastuzumab treatment of HER2+ breast cancer cells (62), and CHD4 silencing improves sensitivity to cisplatin and PARP1 inhibitor in TNBC cells (25, 26).